PrEP During Breastfeeding: Truvada vs Apretude
Daily oral Truvada (TDF/FTC) is safe and recommended for HIV pre-exposure prophylaxis while breastfeeding, whereas Apretude (cabotegravir) should be avoided during lactation due to insufficient safety data. 1
Truvada (TDF/FTC) During Breastfeeding
Safety Profile and Recommendation
TDF/FTC is the recommended PrEP regimen for breastfeeding individuals, with extensive safety data demonstrating minimal infant drug exposure and no adverse developmental outcomes. 1
Breastfeeding women who become pregnant on cabotegravir should switch to daily oral TDF/FTC and continue this regimen throughout breastfeeding. 1
Infant Drug Exposure Data
The evidence strongly supports minimal clinically significant infant exposure:
Tenofovir was undetectable in 94% of breastfed infant plasma samples in a prospective study of 50 mother-infant pairs receiving daily TDF/FTC PrEP. 2
Emtricitabine was detectable in 96% of infant samples but at extremely low concentrations (median 13.2 ng/mL). 2
The estimated infant doses from breast milk were 12,500-fold lower for tenofovir and >200-fold lower for emtricitabine compared to proposed therapeutic infant doses (0.47 μg/kg for tenofovir vs 6 mg/kg therapeutic dose; 31.9 μg/kg for emtricitabine vs therapeutic dose). 2
Breast milk concentrations remained stable throughout the dosing interval, with median trough-to-peak ratios of 1.0 for tenofovir and 0.8 for emtricitabine, indicating consistent low-level exposure. 2
Comparative Exposure Across Developmental Stages
Breastfed infants are exposed to only 0.5-16% of the tenofovir dosage that fetuses experience via placental transfer, and just 0.01-0.04% of the recommended weight-adjusted therapeutic dose. 3
This negligible exposure level, combined with established safety data from in utero exposure and pediatric treatment studies, provides strong reassurance for breastfeeding mothers. 3, 4
Clinical Outcomes
Multiple systematic reviews found no statistically significant differences in infant mortality, growth parameters, laboratory abnormalities, or bone markers between TDF-exposed and non-TDF-exposed breastfed infants. 4
No serious adverse effects were recorded in prospective studies of breastfeeding women taking TDF/FTC for PrEP. 2
The safety risk profile for TDF/FTC during breastfeeding is well-established from both HIV treatment and PrEP contexts. 5, 6
Apretude (Cabotegravir) During Breastfeeding
Contraindication and Lack of Safety Data
The FDA label explicitly states there are no data on the presence of cabotegravir in human milk, its effects on breastfed infants, or effects on milk production. 7
Animal studies demonstrate that cabotegravir is present in rat milk and was detected in nursing pup plasma, indicating the drug crosses into milk and is absorbed by offspring. 7
When a drug is present in animal milk, it is likely present in human milk, creating potential risks including adverse reactions in breastfed infants and development of viral resistance if HIV acquisition occurs. 7
Clinical Guidance
CDC guidelines explicitly recommend continuing daily oral TDF/FTC during breastfeeding rather than returning to cabotegravir. 1
If a patient is not breastfeeding postpartum, returning to cabotegravir may be considered, but only after breastfeeding has ceased. 1
The limited number of cabotegravir-exposed pregnancies and complete absence of lactation safety data contrasts sharply with the extensive experience with TDF/FTC. 1
Key Clinical Considerations
Monitoring Requirements
Quarterly HIV testing must be maintained throughout breastfeeding while on PrEP to verify continued HIV-negative status. 1
For individuals on TDF/FTC, routine monitoring for renal function and bone health should follow standard PrEP protocols, though these concerns are primarily maternal rather than infant-related. 8
Common Pitfalls to Avoid
Do not discontinue effective PrEP during breastfeeding due to unfounded safety concerns about TDF/FTC—the evidence overwhelmingly supports its safety with negligible infant exposure. 2, 3
Do not initiate or continue cabotegravir during breastfeeding given the absence of human safety data and evidence of drug transfer in animal models. 1, 7
Recognize that the indirect benefit of preventing maternal HIV acquisition during breastfeeding (which would pose substantial transmission risk to the infant) far outweighs the minimal theoretical risks from TDF/FTC exposure. 5
Risk-Benefit Assessment
The potential for minimal drug exposure via breast milk is substantially outweighed by HIV prevention benefits, including indirect protection to the infant by preventing maternal HIV acquisition during the high-risk breastfeeding period. 5
Maternal HIV acquisition during breastfeeding, associated with high primary viremia, substantially increases vertical transmission risk—a far greater threat than the negligible drug exposure from TDF/FTC. 6